Full-Time
Medical and cosmetic dermatology services
$21 - $24.50/hr
San Mateo, CA, USA
In Person
See people who can refer or advise you
Schweiger Dermatology Group provides medical and cosmetic dermatology services to a wide patient base. It treats conditions like acne and skin cancer, performs mole removal, and offers cosmetic procedures such as laser treatments, Botox, and hair restoration. The company runs in-person visits and telemedicine appointments, with same-day access to care to improve convenience. Treatments are delivered by dermatology clinicians during visits or virtual consultations, and safety protocols are emphasized, especially during the COVID-19 era. Compared with competitors, Schweiger Dermatology stresses a patient-centric model with broad service offerings, quick access, and multiple care formats (in-office and telemedicine). Its goal is to make dermatology care safe, accessible, and comprehensive for routine skin care and specialized medical treatments.
Company Size
1,001-5,000
Company Stage
Growth Equity (Venture Capital)
Total Funding
$177.7M
Headquarters
New York City, New York
Founded
2010
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Flexible Work Hours
Schweiger named to the 2026 Inc. 5000 list of fastest-growing private companies in America for the 10th consecutive year. NEW YORK, Aug. 20, 2026 /PRNewswire/ - Schweiger, one of the nation's leading dermatology and allergy care practices, announced that it has been named to the 2026 Inc. 5000 list of the fastest-growing private companies in America. This marks the 10th consecutive year Schweiger has earned a spot on the prestigious list, a milestone few companies in any industry achieve. The Inc. 5000 ranks the fastest-growing private companies in the United States based on revenue growth over a three-year period. Companies on the list represent some of the most dynamic segments of the U.S. economy and earning a spot for a full decade running places Schweiger among a small group of repeat honorees. Over the past year, Schweiger has continued to expand its footprint through new office openings and strategic acquisitions, broadened access to care with same-week and same-day appointments, and invested in advanced treatment options, including innovations in skin cancer detection and care. Today, the practice serves patients through a growing national network of offices, offering medical, cosmetic, and surgical dermatology as well as allergy and asthma services through Schweiger Allergy & Asthma. "Being named to the Inc. 5000 for the tenth year in a row is an incredible milestone, and one that belongs to every provider and team member who shows up each day committed to our patients," said Dr. Eric Schweiger, founder and CEO of Schweiger. "When I started this practice, the goal was simple: eliminate long wait times and make high-quality dermatology care accessible to everyone who needs it. A decade of consistent growth tells us that mission continues to resonate, and we're just as focused on the next ten years as we were on our first." About Schweiger. Schweiger Dermatology is a leading national dermatology practice, providing medical, cosmetic, and surgical dermatology, as well as allergy and asthma services through Schweiger Allergy & Asthma. Built around the needs of patients, Schweiger is committed to delivering high-quality, personalized care while removing barriers to access. With a focus on convenience, timely appointments, and clinical excellence, the practice makes expert skin, allergy and asthma care easier to get - often within days, with same- and next-day appointments available. Learn more at schweigerderm.com.
Obagi Medical, part of Waldencast plc, has partnered with Schweiger Dermatology for its ALOHA Programme to generate real-world evidence for Obagi saypha MagIQ injectable. Schweiger was selected for its clinical excellence and extensive national network. The collaboration includes two initiatives: a Phase 4 clinical study led by Dr David Goldberg in Hackensack, and a real-world evaluation programme across select Schweiger aesthetic locations. Programme activities are expected to begin in early 2026. Schweiger will present initial findings at internal leadership meetings and industry conferences. Dr Goldberg noted the partnership aligns with Schweiger's focus on accessible, high-quality care, whilst Drew Fine, Obagi's US General Manager, emphasised the company's commitment to launching the injectable with robust clinical evidence.
NEW YORK, Feb. 5, 2025 /PRNewswire/ -- Schweiger Dermatology Group, a leading provider of dermatology and allergy care, is proud to announce it has been awarded eight Accolades by Castle Connolly. Accolades recognize health systems, hospitals and physician practices that deliver exceptional healthcare through their highly esteemed Castle Connolly Top Doctor physicians.Schweiger Dermatology Group received the following Castle Connolly Accolades for 2025:#1 for Dermatology in New York#1 for Dermatology in New York City#1 for Dermatology in Pennsylvania#1 for Dermatology in Philadelphia#1 for Dermatology in New Jersey#3 for Dermatology in Florida#2 Nationally in Dermatology#2 Nationally in Cosmetic and Reconstructive CareIn addition, 61 Schweiger Dermatology Group physicians have been recognized as Castle Connolly Top Doctors for 2025. This prestigious honor highlights the exceptional expertise and dedication of medical professionals across a growing number of specialties and locations nationwide. Castle Connolly is renowned for its rigorous selection process for Top Doctors, which involves peer nominations, research and a thorough vetting process by a physician-led research team."We are dedicated to delivering the highest level of care and innovation in dermatology and allergy," said Dr. Eric Schweiger, founder and CEO of Schweiger Dermatology Group
DSA was part of the NavaDerm platform formed in 2018.
FORT LAUDERDALE, Fla. and NEW YORK, Nov. 15, 2024 /PRNewswire/ -- NavaDerm Partners, LLC ("NavaDerm" or the "Company"), a dermatology platform and portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), announced the exit of Dermatology and Surgery Associates ("DSA") to Schweiger Dermatology Group ("SDG"). DSA was part of the NavaDerm platform formed in 2018. Vera Abramova, Chief Financial Officer of NavaDerm Partners, LLC said, "We are pleased to announce this is the third practice sold to SDG in the past year. Our remaining flagship practices - Laser Skin Surgery of New York with locations at 34th Street (NYC) and Southampton and our growing Spring Street practice with NYC locations in SoHo and Uptown, continue to benefit from the tailwinds in cosmetic dermatology."